Search hospitals > Texas > San Antonio

South Texas Accelerated Research Therapeutics

Claim this profile
San Antonio, Texas 78229
Global Leader in Solid Tumors
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
233 reported clinical trials
7 medical researchers
Photo of South Texas Accelerated Research Therapeutics in San AntonioPhoto of South Texas Accelerated Research Therapeutics in San AntonioPhoto of South Texas Accelerated Research Therapeutics in San Antonio

Summary

South Texas Accelerated Research Therapeutics is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. South Texas Accelerated Research Therapeutics is involved with conducting 233 clinical trials across 160 conditions. There are 7 research doctors associated with this hospital, such as Amita Patnaik, MD, Drew W Rasco, MD, Kyriakos Papadopoulos, MD, and Kyri Papadopoulos, MD.

Area of expertise

1Solid Tumors
Global Leader
South Texas Accelerated Research Therapeutics has run 117 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive
2Tumors
Global Leader
South Texas Accelerated Research Therapeutics has run 109 trials for Tumors. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at South Texas Accelerated Research Therapeutics

Solid Tumors
Tumors
Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Esophageal Cancer
Pancreatic Cancer
Squamous Cell Carcinoma
Prostate Cancer
Colorectal Cancer
Image of trial facility.

Pembrolizumab

for Advanced Cancers

Recruiting2 awards Phase 34 criteria
Image of trial facility.

PM54

for Solid Tumors

The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - expansion) will be to evaluate the antitumor activity of PM54 in terms of clinical benefit (response or stable disease [SD] ≥4 months associated with tumor shrinkage), according to the RECIST v.1.1 and/or serum markers as appropriate, in patients with selected advanced solid tumors.
Recruiting1 award Phase 1
Image of trial facility.

ABBV-303 + Budigalimab

for Solid Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 181 adult participants will be enrolled in the study across sites worldwide. In Part A, ABBV-303 will be intravenously (IV) infused in escalating doses as a monotherapy in participants with relapsed (R)/refractory (R) solid tumors, R/R non-small cell lung cancer (NSCLC), R/R renal cell carcinoma (RCC), R/R head and neck squamous cell carcinoma (HNSCC), or R/R tissue agnostic participants with mesenchymal epithelial transition. In Part B, ABBV-303 in combination with budigalimab will be IV infused in participants with R/R solid tumors or NSCLC. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Recruiting1 award Phase 14 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at South Texas Accelerated Research Therapeutics?
South Texas Accelerated Research Therapeutics is a medical facility located in San Antonio, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. South Texas Accelerated Research Therapeutics is involved with conducting 233 clinical trials across 160 conditions. There are 7 research doctors associated with this hospital, such as Amita Patnaik, MD, Drew W Rasco, MD, Kyriakos Papadopoulos, MD, and Kyri Papadopoulos, MD.